Biotech Values

[DewDiligence]

MNTA – That was a thin-skinned reply by you. For the record, this is what I said in #31862:

>>
Two points:
1. The deal does not have an up-front signing fee per se—the initial $75M is all in the form of an equity sale.
2. MNTA now has essentially all of its future tied up with a single company (NVS). I think it would have been more bullish if MNTA had inked a major deal with a different partner.
--
MNTA’s valuation is not that cheap. Those who got out near today’s high (20.98) probably made a wise move, IMHO.
<<

I find it amusing that you consider this an justified bash.

>Contrast this to IDIX, whose hepatitis deals are with whom? Novartis.<

What does MNTA have to do with IDIX? They are playing in totally different arenas.

IDIX, by the way is not an independent company—it’s a majority-owned subsidiary of NVS. Hence, noting that IDIX is partnered with NVS in hepatitis is not especially illuminating.